Lifirafenib
Lifirafenib (Beigene-283) is a potent, dual-targeting inhibitor of RAF kinases and EGFR. It demonstrates strong biochemical activity against BRAFV600E and EGFR mutants, including T790M/L858R. This profile supports its research use in studying oncogenic signaling and evaluating therapeutic potential in relevant cancer models, both in vitro and in vivo.
Product Specifications
CAS Number
1446090-79-4
Product Name Alternative
C-RAF (Y340/341D), BGB 283, BGB283, BGB-283, Beigene-283, BRAF WT, BRAF (V600E), B-Raf (V600E), Lifirafenib, inhibit, Epidermal growth factor receptor, ErbB-1, EGFR, EGFR (L858R/T790M), HER1, Inhibitor, WT A-RAF, Raf kinases, Raf
Field of Research
Cardiovascular Research, Signal Transduction
Purity
97.99% (May vary between batches)
Solubility
DMSO:100 mg/mL (209.02 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (8.36 mM)
Smiles
[H][C@]12Oc3ccc (Oc4ccnc5NC (=O) CCc45) cc3[C@@]1 ([H]) [C@@H]2c1nc2ccc (cc2[nH]1) C (F) (F) F
Molecular Formula
C25H17F3N4O3
Molecular Weight
478.42
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
201-15-0159 96 Tests
Canine Matrix metalloproteinase 2/Gelatinase A (MMP-2) ELISA Kit
Sign In for Pricing
View Details 